RecruitingNCT05799118
Study of the Role of Genetic Modifiers in Hemoglobinopathies
Studying Sickle cell disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cyprus Institute of Neurology and Genetics
- Principal Investigator
- Petros Kountouris, PhDCyprus Institute of Neurology and Genetics
- Intervention
- GWAS(genetic)
- Enrollment
- 30000 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2022 – 2027
Study locations (26)
- Boston Children's Hospital, Boston, Massachusetts, United States
- Lucrecia Paím Maternity, Luanda, Angola
- University of Buenos Aires, Buenos Aires, Argentina
- University Hospitals Leuven, Leuven, Belgium
- Universiti Brunei Darussalam, Brunei, Brunei
- Larnaca General Hospital, Larnaca, Cyprus
- Limassol General Hospital, Limassol, Cyprus
- Archbishop Makarios III Hospital, Nicosia, Cyprus
- Paphos General Hospital, Paphos, Cyprus
- Centre Hospitalier Monkole, Kinshasa, Democratic Republic of the Congo
- Rigshospitalet, Copenhagen, Denmark
- Hippokrateio Hospital of Athens, Athens, Greece
- Laiko General Hospital, Athens, Greece
- National and Kapodistrian University of Athens, Athens, Greece
- General Hospital of Larissa, Larissa, Greece
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05799118 on ClinicalTrials.govOther trials for Sickle cell disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT06979492Prophylactic Transfusion In Pregnant in Women With Sickle Cell DiseaseEmory University
- RECRUITINGNCT07392216Functional Ovarian Reserve in Sickle Cell DiseaseSt. Jude Children's Research Hospital
- RECRUITINGNANCT07246265Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive CareUniversity Hospital, Tours
- ENROLLING BY INVITATIONPHASE2NCT07401823Open-Label Extension Study to Pioneer Study 6058-SCD-101Fulcrum Therapeutics
- RECRUITINGPHASE1, PHASE2NCT07432867Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.Assistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07222475Writing Relaxing Beats in Adolescents Who Have Sickle Cell DiseaseMayo Clinic
- RECRUITINGPHASE2NCT07224360Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)CSL Behring
- RECRUITINGPHASE3NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi